Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The site footer now identifies the platform as revision v3.8.0 instead of v3.7.2; the study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T03:58:30.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    A notice announces an NIH website transition and says “Super Intelligence” is replacing “Artificial Intelligence” in some NIH content. It appears above the unavailable study record.
    Difference
    1%
    Check dated 2026-10-25T04:25:47.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier changed from v3.7.1 to v3.7.2 while the page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-18T04:30:18.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T08:17:54.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, blocking access to the study record content and replacing the usual page with a site-wide error message.
    Difference
    0.5%
    Check dated 2026-09-27T06:59:40.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The page pruned the Study Documents area, removing items like the Study Protocol and Statistical Analysis Plan, along with investigator names and historical submission details. This narrows access to essential study documentation and historical context within the record.
    Difference
    19%
    Check dated 2026-09-20T02:24:29.000Z thumbnail image

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.